Prohealth Ltd, a leader within the Maltese pharmaceutical, healthcare, dermo-cosmetic, and medical device markets, has been appointed exclusive agent for Vega Nutritionals and its brands Vega Vitamins and Pro-Ven Probiotics in Malta.

Vega Nutritionals is an innovative, UK-based premium quality manufacturer with over 25 years of experience in the nutritional supplement industry.

Vega Vitamins, a household name on the islands for more than 20 years, offers a wide range of vitamins and minerals to support specific health needs.

Pro-Ven Probiotics contain a propriety blend of Lab4® probiotic strains. These have featured in a wide variety of clinical studies, making Pro-Ven and its Lab4® probiotic strains the most widely clinically studied probiotic worldwide today. Vega Vitamins and Pro-Ven Probiotics are now widely available in pharmacies across Malta and Gozo.

Prohealth vega nutritionals

Prohealth was founded in 1995 and has grown from a small team led by its founders to a fast-developing 60-strong team in Malta and overseas. Market-leading brands represented include La Roche-Posay, Vichy and CeraVe skincare, Rowex generic pharmaceuticals, and popular OTC names such as Hysan, Muciclar, Hylo-COMOD, and Clinell wipes. Prohealth has also been increasing its presence and activity within the medical devices hospital market.

Related

Bank of Valletta: Pioneering the future of digital payments in Malta

October 31, 2024
by Sarah Muscat Azzopardi

Chris Degabriele, Head of eBanking, reflects on the bank’s exciting digital transformation journey, which is closely linked to his own.

ECB lowers key interest rates by 25 basis points in response to inflation outlook

September 12, 2024
by Helena Grech

While inflation remains high, the ECB projects it will ease in the second half of next year

HSBC Malta share price drops sharply following strategic review announcement

September 11, 2024
by Helena Grech

Market analysts suggest that the uncertainty surrounding the review, with speculation of an impending sale, has fuelled investor concerns